[ CAS No. 874-10-2 ] {[proInfo.proName]}

Name: 874-10-2|8-Methylimidazo[1,2-a]pyridine|95%
Brand: Ambeed
SKU: A267676
Price: 5.0 USD
Availability: InStock
Rating: 90 (26 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 874-10-2

Structure of 874-10-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 874-10-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 874-10-2 ]

SDS Specification

Alternatived Products of [ 874-10-2 ]

Product Details of [ 874-10-2 ]

CAS No. :	874-10-2	MDL No. :	MFCD05663805
Formula :	C₈H₈N₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	BJZAXTJBEBNEDL-UHFFFAOYSA-N
M.W :	132.16	Pubchem ID :	327957
Synonyms :

Calculated chemistry of [ 874-10-2 ] Expand+

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.12
Num. rotatable bonds :	0
Num. H-bond acceptors :	1.0
Num. H-bond donors :	0.0
Molar Refractivity :	40.16
TPSA :	17.3 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.59 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.88
Log Po/w (XLOGP3) :	2.13
Log Po/w (WLOGP) :	1.64
Log Po/w (MLOGP) :	1.05
Log Po/w (SILICOS-IT) :	1.45
Consensus Log Po/w :	1.63

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.67
Solubility :	0.284 mg/ml ; 0.00215 mol/l
Class :	Soluble
Log S (Ali) :	-2.12
Solubility :	0.992 mg/ml ; 0.0075 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.44
Solubility :	0.483 mg/ml ; 0.00366 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.35

Safety of [ 874-10-2 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280	UN#:	N/A
Hazard Statements:	H302-H317	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 874-10-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 874-10-2 ]
Downstream synthetic route of [ 874-10-2 ]

[ 874-10-2 ] Synthesis Path-Upstream 1~4

1
[ 1603-40-3 ]
[ 2032-35-1 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
98%	With hydrogen bromide In ethanol; water at 90℃; for 26 h;	2-amino-3-methylpyridine (10 g, 92.5 mmol) and 2-bromo-1,1-diethoxyethane (36.4 g, 185 mmol) were dissolved in ethanol (100 mL) Then, 48percent aqueous hydrogen bromide solution (9 mL) was slowly added dropwise to the reaction solution. After the reaction system was heated to 90 ° C for 26 hours, LC-MS detection reaction has ended, And then cooled to room temperature. The first reaction in the system of ethanol decompression distillation, The excess hydrobromic acid in the reaction was neutralized with excess saturated sodium bicarbonate water (100 mL) and sodium bicarbonate solids (15 g). The remaining mixture was extracted with ethyl acetate (200 mL x 3) All organic phases were then mixed and washed once with deionized water (100 mL) and saturated brine (100 mL) Dried over anhydrous sodium sulfate, Press the steam to remove the solvent. The remaining mixture was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 0-10percent), To give 8-methyl-imidazo [1,2-a] pyridine (12 g, yield 98percent).

Reference： [1] Patent: CN106279160, 2017, A, . Location in patent: Paragraph 0259; 0263; 0264; 0265
[2] Bulletin of the Chemical Society of Japan, 1999, vol. 72, # 6, p. 1327 - 1334

2
[ 107-20-0 ]
[ 1603-40-3 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
62%	With sodium chloride; sodium hydrogencarbonate In water	EXAMPLE IV 8-METHYLIMIDAZO[1,2-A]PYRIDINE To a mixture of chloroacetaldehyde [25.4 mL (0.2 mole) of a 50percent aqueous solution]and 18.8 g (0.2 mole) of 2-amino-3-methylpyridine in 150 mL of water was added 16.8 g (0.2 mole) of sodium bicarbonate. After being stirred at 25° C. for 3 days, the mixture was acidified with concentrated hydrochloric acid and stirred an additional 30 minutes. After the pH was adjusted to 10 by addition of sodium hydroxide, the mixture was saturated with sodium chloride and extracted with ether. The ether extracts were dried and concentrated to give 16.3 g (62percent) of a liquid residue, bp 68°-70° C. at 0.1 Torr. Imidazo[1,2-a]pyridine, bp 61°-66° C. at 0.1 Torr., was prepared in an analogous manner.

Reference： [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 23, p. 4415 - 4424
[2] Patent: US5039691, 1991, A,
[3] Patent: EP1790650, 2007, A1, . Location in patent: Page/Page column 45

3
[ 637-81-0 ]
[ 136117-74-3 ]
[ 1033434-57-9 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
10%	Stage #1: at -30℃; Stage #2: at -30 - 20℃;	Preparation of ethyl imidazopyridine propenoate (According to the Literature Method: Chezal, J. M. and al. J. Org. Chem. 2001, 66, 6576-6584).Ethyl azidoacetate (1.81 g, 14.0 mmol) was added dropwise at -30° C. to a stirred solution containing sodium (0.20 g, 8.70 mmol) in dry ethanol (10 mL). To this solution was added dropwise a solution of aldehyde 4 (1.00 mmol) in dry ethanol (8 mL). The reaction mixture was returned back room temperature and stirred for 3 h (CAUTION: an exothermic reaction can take place, with gas expansion). The solution was poured into aqueous saturated ammonium chloride solution (30 mL) and then extracted with CH₂Cl₂. The organic layers were dried (Na₂SO₄), filtered and evaporated in vacuo. The crude product was purified by chromatography using CH₂Cl₂as eluent to afford the azide derivative 6; Example 35 Ethyl α-azido-β-(imidazo[1,2-a]pyridin-8-yl)propenoate (6a) From 4a (yield: 10percent); mp: 150-152° C.; IR (KBr) 2100, 1700, 1600, 1280 cm^-1; ¹H NMR (400 MHz, CDCl₃) δ 1.41 (t, 3H, J=7 Hz), 4.39 (q, 2H, J=7 Hz), 6.83 (t, 1H, J=7 Hz), 7.57 (d, 1H, J=1 Hz), 7.61 (d, 1H, J=1 Hz), 7.76 (s, 1H), 8.06 (dd, 1H, J=7, 1 Hz), 8.17 (dd, 1H, J=7, 1 Hz). MS m/z 257 (M⁺, 1), 229 (61), 183 (100), 155 (31), 129 (23), 104 (14). Further elution gave 8-methylimidazo[1,2-a]pyridine (yield: 10percent-Kaiser, C. and al. J. Med. Chem. 1992, 35, 4415-4424).

Reference： [1] Patent: US2010/93781, 2010, A1, . Location in patent: Page/Page column 22

4
[ 1603-40-3 ]
[ 17157-48-1 ]
[ 874-10-2 ]

Reference： [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 14, p. 2856 - 2859

[ 874-10-2 ] Synthesis Path-Downstream 1~64

1
[ 107-20-0 ]
[ 1603-40-3 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
16.3 g (62%)	With sodium chloride; sodium hydrogencarbonate; In water;	EXAMPLE IV 8-METHYLIMIDAZO[1,2-A]PYRIDINE To a mixture of chloroacetaldehyde [25.4 mL (0.2 mole) of a 50% aqueous solution]and 18.8 g (0.2 mole) of 2-amino-3-methylpyridine in 150 mL of water was added 16.8 g (0.2 mole) of sodium bicarbonate. After being stirred at 25 C. for 3 days, the mixture was acidified with concentrated hydrochloric acid and stirred an additional 30 minutes. After the pH was adjusted to 10 by addition of sodium hydroxide, the mixture was saturated with sodium chloride and extracted with ether. The ether extracts were dried and concentrated to give 16.3 g (62%) of a liquid residue, bp 68-70 C. at 0.1 Torr. Imidazo[1,2-a]pyridine, bp 61-66 C. at 0.1 Torr., was prepared in an analogous manner.
		18.27 g of 2-amino-3-picoline was dissolved in 150 mL of water, 14.2 g of sodium hydrogen carbonate and 33.2 g of chloroacetaldehyde (40% aqueous solution) were added thereto, and then stirred at room temperature for 4 hours. The solution was adjusted to pH 10 with a 3N aqueous solution of sodium hydroxide, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and then dried over anhydrous sodium sulfate. The insolubles were separated by filtration, and then the filtrate was concentrated to obtain 8-methylimidazo[1,2-a]pyridine [3-1] as a brown oily product.

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4415 - 4424
[2]Patent: US5039691,1991,A
[3]Patent: EP1790650,2007,A1 .Location in patent: Page/Page column 45

2
[ 137415-94-2 ]
[ 874-10-2 ]
8-Methyl-1-(5-oxo-4,4-diphenyl-tetrahydro-furan-2-ylmethyl)-1H-imidazo[1,2-a]pyridin-4-ylium; chloride [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4415 - 4424

3
[ 874-10-2 ]
[ 74-88-4 ]
[ 10518-69-1 ]

Reference： [1]Tetrahedron,1981,vol. 37,p. 91 - 95

4
[ 874-10-2 ]
[ 137415-93-1 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;Raney nickel; In butan-1-ol; at 65℃; under 3800.26 Torr; for 96.0h;	1 g of <strong>[874-10-2]8-methylimidazo[1,2-a]pyridine</strong> [3-1] was dissolved in 20 mL of 1-butanol, and a catalytic amount of Raney nickel of was added thereto. The mixture was stirred under a hydrogen atmosphere (5 atmospheric pressure) at 65C for 4 days. After cooling the reaction mixture back to room temperature, the insolubles were filtered through celite, and washed with methanol. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, to obtain 823.3 mg of 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine [46-1].

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4415 - 4424
[2]Patent: EP1790650,2007,A1 .Location in patent: Page/Page column 58

5
[ 1603-40-3 ]
[ 17157-48-1 ]
[ 874-10-2 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

6
[ 68-12-2 ]
[ 874-10-2 ]
[ 175878-16-7 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

7
[ 1603-40-3 ]
[ 2032-35-1 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
98%	With hydrogen bromide; In ethanol; water; at 90℃; for 26.0h;	2-amino-3-methylpyridine (10 g, 92.5 mmol) and 2-bromo-1,1-diethoxyethane (36.4 g, 185 mmol) were dissolved in ethanol (100 mL) Then, 48% aqueous hydrogen bromide solution (9 mL) was slowly added dropwise to the reaction solution. After the reaction system was heated to 90 C for 26 hours, LC-MS detection reaction has ended, And then cooled to room temperature. The first reaction in the system of ethanol decompression distillation, The excess hydrobromic acid in the reaction was neutralized with excess saturated sodium bicarbonate water (100 mL) and sodium bicarbonate solids (15 g). The remaining mixture was extracted with ethyl acetate (200 mL x 3) All organic phases were then mixed and washed once with deionized water (100 mL) and saturated brine (100 mL) Dried over anhydrous sodium sulfate, Press the steam to remove the solvent. The remaining mixture was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 0-10%), To give 8-methyl-imidazo [1,2-a] pyridine (12 g, yield 98%).

Reference： [1]Patent: CN106279160,2017,A .Location in patent: Paragraph 0259; 0263; 0264; 0265
[2]Bulletin of the Chemical Society of Japan,1999,vol. 72,p. 1327 - 1334

9
[ 874-10-2 ]
[ 372147-47-2 ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

10
[ 874-10-2 ]
[ 1033434-65-9 ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

11
[ 874-10-2 ]
(Z)-5-(2-bromoimidazo[1,2-a]pyridin-8-yl)methylidene-3-ethylimidazolin-2-methoxy-4-one [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

12
[ 874-10-2 ]
(Z)-5-[(2-bromoimidazo[1,2-a]pyridin-8-yl)methylidene]-1H-3-ethylimidazolidin-2,4-dione [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

13
[ 874-10-2 ]
[ 372147-62-1 ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

14
[ 874-10-2 ]
[ 372147-48-3 ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

15
[ 874-10-2 ]
ethyl 2-bromoimidazo[1.2-a]pyrrolo[3,2-c]pyridin-8-carboxylate [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

16
[ 874-10-2 ]
3-(2-bromo-imidazo[1,2-<i>a</i>]pyridin-8-yl)-2-ethyliminomethyleneamino-acrylic acid ethyl ester [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

17
[ 874-10-2 ]
2-bromo-9-ethoxycarbonyl-7-(N-ethylamino)imidazo[2,1-a][2,6]naphthyridine [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2001,vol. 66,p. 6576 - 6584

18
[ 874-10-2 ]
[ 1019024-12-4 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

19
[ 874-10-2 ]
3-Ethylsulfanylmethyl-8-methyl-imidazo[1,2-a]pyridine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

20
[ 874-10-2 ]
2-(8-Methyl-imidazo[1,2-a]pyridin-3-ylmethylsulfanyl)-ethanol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

21
[ 874-10-2 ]
3-Benzylsulfanylmethyl-8-methyl-imidazo[1,2-a]pyridine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

22
[ 874-10-2 ]
[ 178488-40-9 ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2856 - 2859

23
[ 874-10-2 ]
8-Methyl-1-(5-oxo-4,4-diphenyl-tetrahydro-furan-2-ylmethyl)-5,6,7,8-tetrahydro-1H-imidazo[1,2-a]pyridin-4-ylium; chloride [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4415 - 4424

24
[ 637-81-0 ]
[ 136117-74-3 ]
[ 1033434-57-9 ]
[ 874-10-2 ]

Yield	Reaction Conditions	Operation in experiment
10%; 10%		Preparation of ethyl imidazopyridine propenoate (According to the Literature Method: Chezal, J. M. and al. J. Org. Chem. 2001, 66, 6576-6584).Ethyl azidoacetate (1.81 g, 14.0 mmol) was added dropwise at -30 C. to a stirred solution containing sodium (0.20 g, 8.70 mmol) in dry ethanol (10 mL). To this solution was added dropwise a solution of aldehyde 4 (1.00 mmol) in dry ethanol (8 mL). The reaction mixture was returned back room temperature and stirred for 3 h (CAUTION: an exothermic reaction can take place, with gas expansion). The solution was poured into aqueous saturated ammonium chloride solution (30 mL) and then extracted with CH2Cl2. The organic layers were dried (Na2SO4), filtered and evaporated in vacuo. The crude product was purified by chromatography using CH2Cl2 as eluent to afford the azide derivative 6; Example 35 Ethyl alpha-azido-beta-(imidazo[1,2-a]pyridin-8-yl)propenoate (6a) From 4a (yield: 10%); mp: 150-152 C.; IR (KBr) 2100, 1700, 1600, 1280 cm-1; 1H NMR (400 MHz, CDCl3) delta 1.41 (t, 3H, J=7 Hz), 4.39 (q, 2H, J=7 Hz), 6.83 (t, 1H, J=7 Hz), 7.57 (d, 1H, J=1 Hz), 7.61 (d, 1H, J=1 Hz), 7.76 (s, 1H), 8.06 (dd, 1H, J=7, 1 Hz), 8.17 (dd, 1H, J=7, 1 Hz). MS m/z 257 (M+, 1), 229 (61), 183 (100), 155 (31), 129 (23), 104 (14). Further elution gave 8-methylimidazo[1,2-a]pyridine (yield: 10%-Kaiser, C. and al. J. Med. Chem. 1992, 35, 4415-4424).

Reference： [1]Patent: US2010/93781,2010,A1 .Location in patent: Page/Page column 22

25
[ 874-10-2 ]
[ 71-43-2 ]
8-methyl-3-phenyl-H-imidazo[1,2-a]pyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77%	With oxygen; palladium diacetate; silver carbonate; Trimethylacetic acid; In N,N-dimethyl-formamide; at 130℃; for 20.0h;	General procedure: imidazo[1,2-a]pyridine 1a (118mg, 1 mmol), benzene ( 2a, 1 mL), Pd(OAc)2 (5 mol%), Ag2CO3(5 mol%) and PivOH (1.2 eq) were stirred in DMF (2 mL) at 130 C equipped with oxygen bag for 20 h. After completion of the reaction (monitored by TLC),the water (10mL) was added. The aqueous solution was extracted with ethyl acetate (3×15 mL) and the combined extract was dried with anhydrous MgSO4.The solvent was removed and the crude product was separated by column chromatography (eluted with petroleum ether : ethyl acetate=21) to give a pure sample of 3a (Yellowoil, 144 mg, yield 74%).

Reference： [1]Tetrahedron Letters,2014,vol. 55,p. 1589 - 1592

26
[ 874-10-2 ]
[ 140-88-5 ]
[ 1642164-60-0 ]

Reference： [1]RSC Advances,2014,vol. 4,p. 32013 - 32016

27
[ 292638-85-8 ]
[ 874-10-2 ]
[ 1642164-59-7 ]

Reference： [1]RSC Advances,2014,vol. 4,p. 32013 - 32016

28
[ 292638-84-7 ]
[ 874-10-2 ]
C₁₆H₁₄N₂ [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 50137 - 50140

29
[ 405-99-2 ]
[ 874-10-2 ]
C₁₆H₁₃FN₂ [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 50137 - 50140

30
[ 1746-23-2 ]
[ 874-10-2 ]
C₁₆H₁₃ClN₂ [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 50137 - 50140

31
[ 292638-85-8 ]
[ 874-10-2 ]
C₁₂H₁₂N₂O₂ [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 50137 - 50140

32
[ 874-10-2 ]
[ 140-88-5 ]
C₁₃H₁₄N₂O₂ [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 50137 - 50140

33
[ 67-68-5 ]
[ 874-10-2 ]
[ 175878-16-7 ]

Yield	Reaction Conditions	Operation in experiment
80%	With iron(III) chloride; oxygen; acetic acid; at 100℃; under 760.051 Torr; for 12.0h;	General procedure: FeCl3 (0.025 mmol, 4 mg) and AcOH (0.1 mmol, 6 mg) was mixed with DMSO (3 mL) in a glass vial or round-bottom flask equipped with a magnetic stirring bar. Then, substrate 1 (0.5 mmol) was added. The mixture was stirred under an dioxygen atmosphere (1 atm) at 100C for 12 h. After cooling down to room temperature, 5 mL of ethyl acetate was added and removal of the DMSO with brine, the residue was purified by flash chromatography on silica gel to obtain the desired product 2 using light petroleum ether/ethyl acetate (4:1, v/v) as eluent, which furnished the 3-formylimidazo[1,2-a]pyridine.

Reference： [1]Chemical Communications,2015,vol. 51,p. 1823 - 1825
[2]Tetrahedron Letters,2016,vol. 57,p. 3870 - 3872

34
[ 149-30-4 ]
[ 874-10-2 ]
C₁₅H₁₁N₃S₂ [ No CAS ]

Reference： [1]Catalysis Communications,2015,vol. 66,p. 83 - 86

35
[ 874-10-2 ]
[ 2382-96-9 ]
C₁₅H₁₁N₃OS [ No CAS ]

Reference： [1]Catalysis Communications,2015,vol. 66,p. 83 - 86

36
[ 874-10-2 ]
[ 131242-36-9 ]
C₁₂H₁₀N₄S [ No CAS ]

Reference： [1]Catalysis Communications,2015,vol. 66,p. 83 - 86

37
[ 371-42-6 ]
[ 874-10-2 ]
C₁₄H₁₁FN₂S [ No CAS ]

Reference： [1]Catalysis Communications,2015,vol. 66,p. 83 - 86

38
[ 1569-69-3 ]
[ 874-10-2 ]
C₁₄H₁₈N₂S [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22356 - 22360

39
[ 874-10-2 ]
[ 112-55-0 ]
C₂₀H₃₂N₂S [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22356 - 22360

40
[ 109-79-5 ]
[ 874-10-2 ]
C₁₂H₁₆N₂S [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22356 - 22360

41
[ 100-53-8 ]
[ 874-10-2 ]
C₁₅H₁₄N₂S [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22356 - 22360

42
[ 107-03-9 ]
[ 874-10-2 ]
C₁₁H₁₄N₂S [ No CAS ]

Reference： [1]RSC Advances,2015,vol. 5,p. 22356 - 22360

43
[ 874-10-2 ]
8-methyl-3-(8-methyl-imidazo[1,2-a]pyridin-3-yl)imidazo[1,2-a]pyridine [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2015,vol. 357,p. 3109 - 3114

44
[ 127-19-5 ]
[ 874-10-2 ]
N,N-dimethyl-2-(8-methylimidazo[1,2-a]pyridin-3-yl)-2-oxoacetamide [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 12725 - 12732

45
[ 685-91-6 ]
[ 874-10-2 ]
N,N-diethyl-2-(8-methylimidazo[1,2-a]pyridin-3-yl)-2-oxoacetamide [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 12725 - 12732

46
[ 874-10-2 ]
[ 67-64-1 ]
1-(2,8-dimethylimidazo[1,2-a]pyridin-3-yl)propane-1,2-dione [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 12725 - 12732
[2]Advanced Synthesis and Catalysis,2016,vol. 358,p. 67 - 73

47
[ 98-86-2 ]
[ 874-10-2 ]
1-(8-methylimidazo[1,2-a]pyridin-3-yl)-2-phenylethane-1,2-dione [ No CAS ]

Reference： [1]Advanced Synthesis and Catalysis,2016,vol. 358,p. 67 - 73

48
[ 109-06-8 ]
[ 874-10-2 ]
(8-methylimidazo[1,2-a]pyridin-3-yl)(pyridin-2-yl)methanone [ No CAS ]

Reference： [1]Organic Letters,2016,vol. 18,p. 3582 - 3585

49
[ 874-10-2 ]
C₂₅H₂₈N₈O₄ [ No CAS ]